Data as of Apr 17
| +0.05 / +0.90%|
The 2 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 8.54, with a high estimate of 12.07 and a low estimate of 5.01. The median estimate represents a +52.79% increase from the last price of 5.59.
The current consensus among 2 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.